KERNX Health review
Washington DC telehealth platform selling compounded semaglutide and tirzepatide on flat monthly plans, with the physician consultation billed separately per visit.
Est. first month
From $129/mo (plus a separate fee, compounded)
- Semaglutide
- From $129/mo (plus a separate fee, compounded)
- Tirzepatide
- From $199/mo (plus a separate fee, compounded)
- Coverage
- Coverage not published
- Brand-name
- Compounded only
The Value Score card
KERNX Health scored on our six published factors. See the methodology.
Why it's a deal
- Publishes plan pricing openly, before any intake or account creation
- Month-to-month with no long-term contract and no multi-month prepayment
- Billing starts only after a licensed provider approves treatment
- LegitScript certification verified against the issued seal, not just the badge
Read the fine print
- Its own pricing page contradicts itself: it claims no separate consultation charges, then states a $25-$60 fee applies per visit
- The consultation fee is charged whether or not a prescription is issued
- Advertised $129 and $199 rates are time-limited founding rates; standard rates are $249 and $299
- No compounding pharmacy is named anywhere on the site
- Shipping claims conflict: a 48-hour figure on the homepage against 1-2 days to ship plus 2-3 days transit in the FAQ
The bottom line
Best for: Shoppers who want plan pricing published up front and month-to-month billing. Washington DC telehealth platform selling compounded semaglutide and tirzepatide on flat monthly plans, with the physician consultation billed separately per visit.
Ranked #172 of 395 programs we track — see our #1 deal, CoreAge Rx, for comparison.
Compare with other deals
The programs scoring closest to KERNX Health, out of 394 others we track.
Shopping KERNX Health against a specific rival? We put it head to head with our top-scoring pick on CoreAge Rx vs KERNX Health, and every program that undercuts or outscores it is ranked on the KERNX Health alternatives board.
- From $95/mo (starting dose, compounded)boostAGErx— boostAGErx is a longevity-focused telehealth brand offering compounded GLP-1 weight management (semaglutide and tirzepatide) starting around $95/mo on a 12-month upfront plan, plus peptide therapy such as…73/100
- From $125/mo (0.25 mg dose, compounded)Citizen Meds— Citizen Meds is a GLP-1/weight-loss injection provider offering semaglutide.73/100
- From $156/mo (compounded)Injectco— Injectco is a Dallas-based medspa offering compounded GLP-1 prescriptions shipped from licensed US partner pharmacies.73/100
- From $149/mo (brand Wegovy)Kin Meds— Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…73/100
- From $135/mo (starting dose, compounded)Livv— Telehealth weight loss provider offering compounded tirzepatide programs.73/100
- From $79/mo (plus a separate fee, compounded)Loop Health— Loop Health is a US telehealth membership platform offering compounded semaglutide and tirzepatide under its Loop Lean program, alongside peptides, NAD+, sermorelin, coaching, and bloodwork.73/100
More programs we track (24)
- #1 CoreAge Rx93
- #2 Ondra Health92
- #4 Vitara RX91
- #5 Gimme Care91
- #7 Alan Meds90
- #3 Trimi Health89
- #10 Precision Telemed89
- #11 bmiMD89
- #12 Care Clinics89
- #6 Oak88
- #16 Live Vital88
- #17 AmberHealth88
- #18 Fresh Day Meds88
- #8 Sesame Care87
- #9 Strut Health87
- #22 EverSlim87
- #23 NewSelf87
- #24 Vaylen87
- #25 Mint Med87
- #13 HealthRX86
- #14 RxSpan MD86
- #15 Sprout Health86
- #28 Bionomy Health86
- #29 BetterMe Rx86
364 more are reviewed too — see every GLP-1 program we track, ranked.
Pricing and coverage on this page were read from KERNX Health's own website on ; the Value Score is our editorial judgment per the methodology. “% vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on KERNX Health's site. Not medical advice; see our disclosure.